Komori
Share Issuance and Disposal4563AnGes,Inc.Pharmaceuticals

Notice of Completion of the Acquisition and Cancellation of the 46th Stock Acquisition Rights (with Exercise Price Adjustment Clause)

The company acquired the 837,171 remaining 46th Series Stock Acquisition Rights and cancelled all of them on 15 September 2026. The number remaining after cancellation was 0.

Worth reading
42Recurring
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
837171
units
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Acquisition and cancellation of the 46th Series Stock Acquisition Rights (with an exercise price adjustment clause)

Terms of the stock acquisition rights
Number of Stock Acquisition Rights
Total number issued: Not disclosed; number acquired and cancelled: 837,171; number remaining after cancellation: 0
Most recent equity financing
The 46th Series Stock Acquisition Rights issued pursuant to a resolution of the Board of Directors held on 7 November 2025 (the detailed amount is not stated in this document)
Impact on Business Performance
The impact of the acquisition and cancellation of the 46th Series Stock Acquisition Rights on consolidated results for the fiscal year ending December 2026 is minor.
Acquisition price
Total amount: ¥27,626,643 (¥33 per stock acquisition right)
Acquisition and cancellation date
15 September 2026
Details of issuance or disposal
ItemDetails
Type of issuance or disposalAcquisition and cancellation of the 46th Series Stock Acquisition Rights (with an exercise price adjustment clause)
Number of Stock Acquisition RightsTotal number issued: Not disclosed; number acquired and cancelled: 837,171; number remaining after cancellation: 0
Most recent equity financingThe 46th Series Stock Acquisition Rights issued pursuant to a resolution of the Board of Directors held on 7 November 2025 (the detailed amount is not stated in this document)
Impact on Business PerformanceThe impact of the acquisition and cancellation of the 46th Series Stock Acquisition Rights on consolidated results for the fiscal year ending December 2026 is minor.
Acquisition priceTotal amount: ¥27,626,643 (¥33 per stock acquisition right)
Acquisition and cancellation date15 September 2026
Items this document does not state (24)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offering

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company states that, based on its press release dated 14 August 2026, it acquired and cancelled all of the 46th Series Stock Acquisition Rights remaining on the acquisition date. The impact on consolidated results for the fiscal year ending December 2026 is expected to be minor.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Completion of the Acquisition and Cancellation of the 46th Stock Acquisition Rights (with Exercise Price Adjustment Clause) | AnGes,Inc. (4563) timely disclosure | Komori